secwatch.observer — SEC 8-K summary
======================================

Issuer:     AETHLON MEDICAL INC (AEMD)
CIK:        0000882291
Form:       8-K
Filed at:   2026-09-17T12:03:36+00:00
Accession:  0001683168-26-007206
Event type: m_and_a
Sentiment:  positive
Materiality: 0.95
Item codes: 1.01, 5.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aethlon Medical to merge with North Immunology in $150M all-stock deal; $180M PIPE backs NOR-101
--------------------------------------------------------------------------------

- All-stock merger values North Immunology at $150M and Aethlon at $16.5M; closing expected by June 17, 2027.
- North Immunology stockholders to own ~95.25% of combined company; Aethlon holders ~4.75%.
- Oversubscribed $180M private placement ($146M cash + $34M notes) funds operations into 2H 2028.
- NOR-101 (IL-13 x IL-18 bispecific) for atopic dermatitis: Phase 1a Q1 2027, Phase 1b/2b data 2028.
- Legacy Aethlon assets to receive contingent value rights (CVRs) with no guaranteed payments.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/882291/000168316826007206/0001683168-26-007206-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/882291/000168316826007206/aethlon_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-26-007206

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer